Abstract. In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was transformed with a ÏZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (MMGL, phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blot analysis revealed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present in 43 (47%) of 91 patients, but in only one (2.2%) of 45 healthy controls. Of the 21 patients with stage I disease, 8 (38%) were sero-positive. The positive rate of s-MMGL-Abs was greater than those of other conventional tumor markers. Reverse transcription-PCR analysis suggested that alternative splicing from myomegalin variant 1 to variant 5 may explain, in part, the development of s-MMGL-Abs. Although the presence of s-MMGL-Abs was not related to any clinicopathological features of the patients, multivariate analysis indicated that the presence of s-MMGL-Abs was significantly associated with a favorable prognosis. Consequently, s-MMGL-Abs may be a useful tumor marker to diagnose and establish a prognosis in patients with esophageal SCC.
Introduction
Esophageal squamous cell carcinoma (SCC) is a deadly disease. Late presentation in a group of elderly patients with co-morbid illnesses resulted in a poor outcome (1, 2) . The aggressive behavior of esophageal SCC has been associated with systemic involvement at diagnosis, and the poor prognosis has been attributed largely to a delay in diagnosis (2) . Although several serum markers have been reported to be clinically useful for diagnosing esophageal SCC (3, 4) , these serum markers are limited in terms of detecting early esophageal cancers, except the serum p53 IgG antibody (5, 6) . In order to identify new tumor-associated antigens that may generate new serum markers for esophageal SCC, we used the method of serological identification of antigens by recombinant cDNA expression cloning (SEREX) which involves the immunoscreening of cDNA libraries prepared from tumor specimens using autologous or allogeneic sera (7). Chen et al (8) and our group (9) (10) (11) (12) (13) have succeeded in the identification of several tumor antigens for esophageal SCC. The identification of human tumor antigens recognized by the autologous host is yielding an array of target molecules for the diagnosis, monitoring, and immunotherapy of human cancer (14) (15) (16) .
In the present study, we identified myomegalin as a new SEREX antigen of esophageal SCC, observed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present frequently in esophageal SCC patients, and associated s-MMGL-Abs with a favorable prognosis in patients with esophageal SCC.
Materials and methods

Human esophageal squamous cell carcinoma cells and tissues.
Seven human esophageal squamous cell carcinoma cell lines and one human immortalized cell line were used. T.Tn was obtained from the Japan Cell Research Bank (Ibaraki, Japan) (17) . TE-10 was obtained from Cancer Cell Repository, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan (18) . The YES-1, YES-2, YES-4, YES-5 and YES-6 were kindly provided by Drs M. Oka and T. Abe (Yamaguchi University Graduate School of Medicine) (19) . WI-38 human fibroblasts were obtained from Riken Bioresource Center (Ibaraki, Japan). Cells were cultured in Dulbecco's modified Eagle's medium (SigmaAldrich, MO, USA), supplemented with 10% heat-inactivated fetal bovine serum. EN-60 cells are human esophageal keratinocytes immortalized via E6 and E7 of human papillomavirus type 16 (20) . Normal esophageal tissue was obtained from patients with esophageal SCC who underwent subtotal esophagectomy. This work was approved by the Ethics Committee of Chiba University Graduate School of Medicine. The collection of tissues and sera was agreed upon by the patients and healthy donors, each provided a written, informed consent.
Sera from patients with esophageal SCC and healthy donors. Sera were obtained from 45 healthy volunteers and 91 patients with esophageal SCC who represented various stages of disease progression before treatment. The patients consisted of 84 men (92%) and 7 women (8%), with a median age of 67 years (range 39-86 years). A total of 48 patients received surgery and 43 patients received chemoradiation therapy. Surgically treated patients were pathologically classified according to the TNM staging system defined by Union of International Cancer classifications (UICC) (21) using resected specimens. Non-surgically treated patients were clinically classified according to TNM/UICC staging system using computed examination, positron emission tomography, endoscopic ultrasonography and cervical ultrasonography examinations (22) . The patient cohort included 21 with stage I, 22 with stage II, 35 with stage III, and 13 with stage IV cancer. Each serum sample was centrifuged at 3,000 × g for 5 min and the supernatant was stored at -80˚C until use. Repeated thawing and freezing of samples were avoided. After treatment, all patients underwent clinical examination and imaging studies on a regular basis for at least 60 months or until death. All patients were followed up for at least 2 years, 51 of 91 patients had died by the end of 2005.
Enzyme immunoassay for CEA, CYFRA21-1, SCC-Ag and serum p53 antibodies. Serum CEA and CYFRA-Ag concentrations were accessed using the Enzymun-Test CEA and Enzymun-Test CYFRA21-1 (Boehringer Mannheim, Mannheim, Germany), respectively. SCC-Ag levels were quantitated in serum using the SCC Test (Abbott Laboratories, Abbott Park, IL). The cut-off values for serum CEA, CYFRA-Ag, and SCC-Ag levels were 4.6 ng/ml, 2.57 ng/ml and 1.5 ng/ml, respectively, in accordance with the manufacturer's instructions. The specificity at these cut-off values is 95% (3, 4) . Serum p53-Ab was assessed by enzyme-linked immunosorbent assay using the anti-p53 ELISA Kit II (Medical & Biological Laboratories, Nagoya, Japan; Trade name: MESACUP anti-p53 Test) as described previously (5, 6) . All samples were considered positive at 1.3 U/ml. The specificity at these cut-off values is 95% (6) .
SEREX screening. Total RNA was prepared from T.Tn cells by the acid guanidinium thiocyanate-phenolchloroform method and purified poly(A) + RNA was obtained using the Oligotex-dT 30 (Super) mRNA Purification Kit (Takara Biochemicals, Kyoto, Japan) according to the manufacturer's instructions (23) . Double-stranded cDNA was synthesized by conventional procedures and ligated into the EcoRI-XhoI site of ÏZAP II phage. The original library size consisted of 1.8×10 6 independent clones. The immunological screening method used was a modification from that used in a previously published study (7, 8) . E. coli XL1-Blue MRF' was infected with ÏZAP II phage and the expression of resident cDNA clones was induced following blotting of infected bacteria onto NitroBind nitrocellulose membranes (Osmonics Inc., Minnetonka, MN) that had been pre-treated with 10 mM isopropyl ß-D-thiogalactoside (IPTG) (Wako Pure Chemicals, Osaka, Japan) for 30 min. The membranes with adhered bacterial proteins were washed three times with TBS-T [20 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Tween-20], and blocking was performed by treatment with 1% protease-free bovine serum albumin (Wako Pure Chemicals) in TBS-T for 1 h. The membranes were exposed to 1:2000-diluted serum for 1 h. After washing with TBS-T three times, the membranes were treated for 1 h with 1:5000-diluted alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). Positive reactions were detected by incubation in a color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl and 5 mM MgCl 2 ] containing 0.3 mg/ml of nitroblue tetrazolium chloride (Wako Pure Chemicals) and 0.15 mg/ml of 5-bromo-4-chloro-3-indolylphosphate (Wako Pure Chemicals). Positive clones were re-cloned twice to obtain monoclonality.
Sequence analysis of identified antigens.
Monoclonalized phage cDNA clones were converted to pBluescript phagemids by in vivo excision using the ExAssist helper phage (Stratagene, La Jolla, CA). Plasmid DNA was obtained from the E. coli SOLR strain following transformation by the phagemid. The cDNA inserts were sequenced by the dideoxy chain termination method using the DNA Sequencing BigDye TM Terminator kit (Applied Biosystems, Foster City, CA) and the ABI PRISM 3700 DNA Analyzer (Applied Biosystems). Sequences were searched for homology with identified genes or proteins contained within public sequence databases using the NCBI-BLAST algorithm.
Western blot analysis. E. coli JM109 cells that contained cDNA clones recombined in pBluescript II were cultured with or without 0.1 mM IPTG for 2.5 h. Cells were then washed with phosphate-buffered saline (PBS) and lysed in SDS sample buffer followed by incubation at 100˚C for 3 min. The lysates were analyzed by Western blotting using sera from 91 patients with esophageal SCC, 16 patients with gastric cancer, 16 patients with colorectal cancer and 45 healthy donors.
Reverse transcriptase-PCR (RT-PCR).
Total cellular RNA was isolated from cultured cells and normal and carcinoma tissues of the esophagus using the AquaPure RNA Isolation kit (Bio-Rad, Hercules, CA). Total RNA of normal esophageal keratinocytes was also purchased from Cybrdi (Gaithersburg, MD). Reverse transcription was performed with an oligo(dT) 20 primer using the ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA). The presence of myomegalin transcripts was examined via PCR amplification using the following primers: MMGLv1-742F, 5'-TGGGAAGATGTACCAGGAGAC-3'; MMGLv1-1023R, 5'-GAGTTCTGCCAAGTGGGAATC-3'; MMGLv1-3029F, 5'-TACGCAGTCGGCTAGAAGAAG-3'; MMGLv1-3368R, 5'-TCCTCCTCAGCTTTCCTCTTC-3'; MMGLv4-1032R, 5'-CTCTTGCTTGCCGCTATTTGC-3'; and MMGLv5-1697F, 5'-CACCTGTGAGTTATCCCTT GG-3'. Actin-specific PCR primers (sense, 5'-GGATCAG CAAGCAGGAGTATG-3'; antisense, 5'-GAGAAGTGGG GTGGCTTTTAG-3') were used as positive controls. PCR was performed using KOD-Plus-DNA polymerase (Toyobo, Osaka, Japan) as follows: an initial denaturation step at 94˚C for 3 min, followed by 30 cycles of denaturation at 94˚C for 30 sec, annealing at 59˚C for 30 sec, and extension at 68˚C for 30 sec, with a final extension of 5 min at 68˚C.
Immunohistochemical analysis. Polyclonal anti-myomegalin serum was developed by immunizing rabbits with glutathione-S-transferase-myomegalin fusion protein that contained a region of the human KIAA0477/myomegalin protein (between amino acid positions 949 and 1148). The anti-sera were obtained 102 days after the first immunization and IgG was purified by using Protein A-Agarose.
Immunohistochemical staining was performed using the Histofine SAB-PO Kit (Nichirei Corporation, Tokyo, Japan) as described (24) . In brief, 4-μm-thick sections were deparaffinized in xylene, dehydrated through graded alcohol concentrations and incubated in citrate buffer (pH 6.0) for 5 min in a household microwave oven at 800 W. After microwave exposure, the slides were allowed to cool to room temperature. The slides were briefly washed with PBS and incubated for 15 min with 3% hydrogen peroxide in methanol to block endogenous peroxidase activity. The antibodies to myomegalin were diluted 1:250 and incubated for 24 h at 4˚C. Biotinylated anti-rabbit IgG antibody (Dako Cytomation, Carpinteria, CA) at a dilution of 1:500 was used as the second antibody. After incubation in avidin-biotin complex solution (Dako Cytomation), the staining was developed by the diaminobenzidine method, followed by counterstaining with Mayer's haematoxylin. The stained sections were evaluated at a high magnification (×400). Staining was considered positive for myomegalin when more than 10% of the cells were stained strongly.
Statistical analyses. Fisher's exact probability test was used to determine the significance of differences between the two groups. Survival probabilities were calculated by the KaplanMeier method. Differences between groups were determined using the log-rank test. The influence of each significant predictor identified by univariate analysis was assessed by multivariate analysis using Cox's proportional hazards model. All statistical analyses were carried out using the StatView program version 5.0 for Windows (SAS Institute Inc., Cary, NC). The difference was considered statistically significant when the P-values were >0.05.
Results
Isolation of myomegalin cDNA by SEREX. The phage expression library was constructed using mRNA derived from the human esophageal squamous cell line, T.Tn. A total of 5x10 6 cDNA clones were screened using sera from five esophageal cancer patients, and >100 reactive clones were isolated. DNA sequence analysis and a search for homologous sequence in NCBI-accessible databases revealed that this grouping consisted of 40 independent clones. One of the isolated cDNA clones was transcript variant 5 of myomegalin (phosphodiesterase 4D interacting protein/PDE4DIP/ CMYA2/ KIAA0477; GenBank accession number: NM_001002811; UniGene: Hs.528503), which was originally cloned by Verde et al as a novel protein that interacts with the cyclic nucleotide phosphodiesterase, PDE4D (25).
Presence of s-MMGL-Abs in patients with esophageal SCC.
To examine for the presence of s-MMGL-Abs, Western blotting was performed using allogeneic sera obtained from 91 patients with esophageal SCC. An example is presented in Fig. 1 . IPTG-pre-treatment of the bacteria induced specific cDNA expression. A positive reaction at 120 kDa was observed only when the extract of IPTG-treated myomegalincDNA-containing bacteria was probed with serum IgG of patient #1, but not with that of healthy donor #1. E. coli that contained the control empty plasmid showed no apparent specific reaction after IPTG treatment. The IPTG-dependent 120-kDa protein appeared to be myomegalin because it also reacted with rabbit polyclonal anti-myomegalin antibody, and its size was similar to the product of cloned myomegalin cDNA (1,102 amino acids). Thus, the results shown in Fig. 1 indicate that patient #1 was positive for s-MMGL-Abs, while healthy donor #1 was negative.
Clinicopathological features of s-MMGL-Abs in the patients with esophageal SCC.
Based on the criteria shown above, sera from 43 (47%) out of 91 patients with esophageal SCC were positive for s-MMGL-Abs. On the other hand, serum from only one (2.2%) of the 45 healthy donors contained a detectable amount of s-MMGL-Abs. Although female patients Figure 1 . The presence of s-MMGL-Abs in patients with esophageal SCC. E. coli containing myomegalin cDNA plasmid (MMGL) or empty pBluescript II vectors (Control) were treated with (+) or without (-) IPTG for 2.5 h, and the total cell lysate was subjected to Western blot analysis using sera of esophageal cancer patient #1 and healthy donor #1 or rabbit anti-myomegalin antibody (anti-MMGL). Arrows indicate the IPTG-dependent specific bands, which represent myomegalin cDNA products or their degradation intermediates. 120 kDa is the size of myomegalin estimated from cDNA sequence, and the smaller sizes of approximately 85, 75, 70 and 50 kDa indicated by asterisks may represent degradation products.
showed a relatively high incidence of s-MMGL-Abs, there was no statistically significant association between the presence of s-MMGL-Abs and the clinicopathological features of the patients (Table I ). The positive rates of s-MMGL-Abs, according to TNM stages, were stage I in 38%, stage II in 45%, stage III in 51%, and stage IV in 54% (Fig. 2A) . The positive rate of s-MMGL-Abs (47%) was higher than those of other conventional tumor markers, such as SCC-Ag (38%), s-p53-Abs (38%), CYFRA21-1 (24%), and CEA (23%) (P=0.29 for SCC-AG and s-p53-Abs, P<0.01 for CEA and CYFRA21-1; Fig. 2B ). The sensitivity was improved by using conventional markers combined with s-MMGL-Abs to 69% with s-p53-Abs, 69% with SCC-Ag, 76% with CYFRA21-1, and 78% with CEA (data not shown).
The s-MMGL-Abs were tested further using serum samples from patients with gastric or colon cancer. s-MMGL-Abs were positive in 12.5% (2/16) of patients with gastric cancer and in 37.5% (6/16) of patients with colon cancer. Thus, the development of s-MMGL-Abs was not limited in esophageal SCC, but was observed in other cancers, showing the possibility for application of s-MMGL-Abs as a marker of other cancers.
Prognostic significance of s-MMGL-Abs in patients with
esophageal SCC. Kaplan-Meier plotting showed that seropositive patients showed better survival rates than seronegative patients, although the difference was not significant (P=0.165, Fig. 3 ). All clinicopathological factors listed in Table I were tested by multivariate analysis and independent prognostic factors were identified using Cox's proportional hazards model. After adjusting for tumor stages, the presence of s-MMGL-Abs was shown to be an independent predictor for favorable survival in patients with esophageal SCC (Table II) .
Expression of myomegalin in esophageal SCC.
The expression levels of myomegalin mRNA in esophageal cell lines were examined by RT-PCR analysis. A total of 27 alternative splicing variants are known for myomegalin/ PDE4DIP mRNA, of which 9 can be translated into proteins (http://www.ensembl.org/Homo_sapiens/index.html). Our preliminary experiments suggested that the myomegalin variants 1, 3, 4 and 5 were expressed more or less in esophageal cells, and, therefore, these variants were examined in detail. The results revealed that the expression of myomegalin variant 1 was observed clearly in normal keratinocytes, immortalized esophageal keratinocytes and T.Tn cells, but was diminished considerably in other esophageal carcinoma cell lines (Fig. 4) . Variant 1 was also expressed in WI-38 normal fibroblasts, but not in MKN74 gastric cancer, DLD1 colon carcinoma, HepG2 hepatoma and PC6 lung Table I . Relationship between s-MMGL-Abs and the clinicopathological variables in 91 patients with squamous cell carcinoma. ----------------------------------------------- 
b P-values were calculated by Fisher's exact probability test. carcinoma cells (Fig. 4, data not shown) . Thus, the expression of myomegalin variant 1 mRNA was low in most tumor cell lines, except T.Tn cells. On the other hand, myomegalin variants 3 and 4 were expressed ubiquitously in all of the cells examined. The expression of myomegalin variant 5 was observed in most of the cell lines examined, but was noticeably low in normal keratinocytes. The expression levels of myomegalin mRNA in normal esophageal tissues and esophageal carcinoma were also examined (Fig. 5) . A higher expression level of myomegalin mRNA was observed in carcinoma tissues compared to that in normal tissues in 4 of 6 patients with esophageal SCC.
Next, we investigated the expression and distribution of myomegalin protein by immunohistochemical analysis in the resected tumor specimens from s-MMGL-Abs-positive patients. The nuclei of each tumor cell showed high immunoreactivity to anti-myomegalin antibodies, whereas normal Table II . Prognostic analysis of patients with esophageal squamous cell carcinoma. 
esophageal tissue showed only weak immunoreactivity, with minimal expression being evident only at the basal lamina (Fig. 6 ).
Discussion
SEREX screening has been performed in esophageal carcinoma by Chen et al, who identified NY-ESO-1 (8) . SEREX antigens are thought to be good candidates for the development of tumor specific vaccination therapies. We have previously reported 21 SEREX antigens of esophageal SCC (9) (10) (11) (12) (13) . In the present study, we identified myomegalin as a new SEREX antigen of great interest.
Myomegalin is composed of ·-helical and coiled-coil structures, with domains shared with microtubule-associated proteins and a leucine zipper (LZ) identical to that found in the Drosophila centrosomin (25) . Myomegalin has also been designated as PDE4DIP because of its binding to the cyclic nucleotide phosphodiesterase, PDE4D (26) . The localization of myomegalin in the Golgi/centrosome suggests that this protein plays a part in transducing cAMP signals in these organelles. Of relevance for this report, myomegalin encodes several putative oligomerization domains capable of activating platelet-derived growth factor receptor ß (PDGFRB). A patient with myeloproliferative disorder was shown to have PDGFRB fused to the PDE4DIP isoform lacking the LZ domain (KIAA0477) (26) . Therefore, the aberrant expression of myomegalin variants may be involved in carcinogenesis.
Myomegalin transcripts consist of 27 variants with up to 46 exons, of which 9 variants can be translated into proteins (http://www.ensembl.org/Homo_sapiens/index.html). The results of RT-PCR revealed that the expression levels of myomegalin variant 5 were higher in esophageal SCC cell lines and tissues than in non-cancerous cells and tissues (Figs. 4 and 5) . On the other hand, the levels of myomegalin variant 1 was diminished in most tumor cell lines compared to that in non-cancerous cells (Fig. 4) . Thus, alternative splicing of the myomegalin gene may account for the development of autoantibodies against myomegalin variant 5.
We evaluated the clinicopathological significance of the presence of s-MMGL-Abs in patients with esophageal SCC. s-MMGL-Abs were present in 47% of patients with esophageal SCC. This positive rate of s-MMGL-Abs was higher than that observed using other tumor markers such as SCC-Ag, s-p53-Abs, CEA and CYFRA21-1. Moreover, s-MMGL-Abs were present in 38% of patients with stage I disease (Fig. 2) . Therefore, s-MMGL-Abs may be a useful marker to detect early esophageal SCC. Apparent absence of association of s-MMGL-Abs with other serum markers led to combinatory assays that increased the positive rates.
Although the patients with s-MMGL-Abs showed advanced disease, the long-term survival of sero-positive patients was better than that of sero-negative patients. Multivariate analysis showed that the presence of s-MMGL-Abs contributed significantly as a favorable prognostic predictor for long-term survival (Table II) . These findings suggest that s-MMGL-Abs may have a role in the suppression of tumor growth. Based on these findings, myomegalin may be proposed as a new target for immunotherapy. Interestingly, tissue distribution of the myomegalin variants varies greatly (27) , and a short 2.4-kb mRNA of myomegalin is specifically expressed in testis (25) . The next step in examining SEREX-defined antigens should be the analysis of the CD4 + and CD8 + T-cell response directed against these antigens (28, 29) . While limited immunotherapy has been reported for esophageal SCC, the clinical application of these tumor antigens, such as in cytotoxic T lymphocyte therapy, is promising (30, 31) . Our results suggest that myomegalin may be a prime candidate for such studies. Figure 6 . Immunoperoxidase staining of formalin-fixed paraffin-embedded esophageal carcinoma tissues using anti-myomegalin antibody. Original magnification, ×400.
